Cargando…
LMD-02. Cerebrospinal Fluid Diversion for Metastatic Leptomeningeal Carcinomatosis: Palliative, Procedural and Oncologic Outcomes
BACKGROUND: Leptomeningeal disease (LMD) occurs in 3–5% of patients with solid metastatic tumors and often portends a severe prognosis including symptomatic hydrocephalus and intracranial hypertension. Cerebrospinal fluid (CSF) shunting can provide symptomatic relief in this patient subset; however,...
Autores principales: | Bander, Evan D, Yuan, Melissa, Reiner, Anne S, Garton, Andrew, Panageas, Katherine S, Brennan, Cameron W, Tabar, Viviane, Moss, Nelson S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351259/ http://dx.doi.org/10.1093/noajnl/vdab071.027 |
Ejemplares similares
-
LMD-21. Headache Improvement Predicts Survival after CSF diversion in Leptomeningeal Disease
por: Robin, Adam, et al.
Publicado: (2021) -
LMD-09. Outcomes and symptom benefit from palliative radiotherapy for leptomeningeal disease in breast cancer patients
por: Takayesu, Jamie, et al.
Publicado: (2021) -
LMD-05. Phase 1B Study of Avelumab and Whole Brain Radiotherapy (WBRT) in Patients with Leptomeningeal Disease (LMD): Preliminary Results
por: Pina, Yolanda, et al.
Publicado: (2021) -
17. MELANOMA BRAIN METASTASIS: PRESENTATION, TREATMENT AND OUTCOMES IN THE AGE OF TARGETED- AND IMMUNO-THERAPIES
por: Bander, Evan D, et al.
Publicado: (2020) -
LMD-10. The role of immune checkpoint inhibitors in leptomeningeal disease: a systematic review
por: Palmisciano, Paolo, et al.
Publicado: (2021)